
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
For years dermatologists have been recognized as the experts in the diagnosis and medical or surgical treatment of diseases and cosmetic disorders of the skin, hair, and nails.